2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
164
Breast Neoplasms
111
Colorectal Neoplasms
77
Neoplasms
65
Lung Neoplasms
61
Pancreatic Neoplasms
56
Stomach Neoplasms
52
Neoplasm Metastasis
51
Ovarian Neoplasms
45
Rectal Neoplasms
43
Esophageal Squamous Cell Carcinoma
38
Esophageal Neoplasms
38
Head and Neck Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
32
Leukemia, Myeloid, Acute
32
Recurrence
26
Triple Negative Breast Neoplasms
25
Small Cell Lung Carcinoma
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Glioblastoma
23
Colonic Neoplasms
23
Uterine Cervical Neoplasms
22
Nasopharyngeal Carcinoma
22
Lymphoma
21
Lymphoma, Non-Hodgkin
20
Fallopian Tube Neoplasms
20
Prostatic Neoplasms
17
Melanoma
17
Sarcoma
16
Leukemia
16
Interventions
Rituximab
112
Cyclophosphamide
103
fludarabine
61
Doxorubicin
33
Vincristine
31
Etoposide
31
Prednisone
30
Lenalidomide
24
ibrutinib
22
fludarabine phosphate
21
Immunotherapy, Adoptive
19
Bendamustine Hydrochloride
19
obinutuzumab
18
Cytarabine
18
pembrolizumab
16
Magnetic Resonance Spectroscopy
16
Bortezomib
14
Specimen Handling
13
Dexamethasone
13
polatuzumab vedotin
12
CT-P10
12
venetoclax
11
pirtobrutinib
11
Gemcitabine
11
Carboplatin
11
glofitamab
10
zanubrutinib
9
Nivolumab
9
Mycophenolic Acid
9
Melphalan
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Drug Therapy
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts